Non-redundant activity of GSK-3α and GSK-3β in T cell-mediated tumor rejection

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Glycogen synthase kinase-3 (GSK-3) positively regulates PD-1 expression in CD8+ T cells.
• GSK-3 inhibition enhances T cell function and tumor growth control.
• GSK-3 exists as two co-expressed isoforms: GSK-3α and GSK-3β.

Purpose of the Study:

• To investigate the distinct roles of GSK-3α and GSK-3β isoforms in T cell function and anti-tumor immunity.
• To elucidate the contribution of each GSK-3 isoform to PD-1 expression and immune cell infiltration in tumors.

Main Methods:

• Conditional gene targeting in mice to generate isoform-specific knockout models (Gsk3a-/-, Gsk3b-/-, Gsk3a/b-/-).
• Assessment of tumor growth suppression and T cell-mediated anti-tumor immunity.
• Analysis of PD-1, IFNγ, and granzyme B expression in T cells.
• Evaluation of CD4+ and CD8+ T cell infiltration into tumors.

Main Results:

• GSK-3β deficiency (Gsk3b-/-) suppressed tumor growth similarly to combined deficiency (Gsk3a/b-/-), while Gsk3a-/- mice showed no significant difference from wild-type.
• This highlights a critical role for GSK-3β in T cell-mediated anti-tumor immunity.
• Individual GSK-3 isoforms differentially affect PD-1, IFNγ, and granzyme B expression.
• The isoforms act synergistically to regulate PD-1 expression and T cell infiltration into tumors.

Conclusions:

• GSK-3 isoforms exhibit non-redundant functions in T cells, with GSK-3β being particularly important for anti-tumor immunity.
• The interplay between GSK-3 isoforms is complex and crucial for controlling tumor immunity.
• Targeting GSK-3 isoforms holds potential for enhancing cancer immunotherapy strategies.